Anda di halaman 1dari 4

David F. Townson Ph.

Monroe, CT 06468 | Home Telephone: 203 268 6297 | Cellular Telephone: 203 445 3793 |

Professional Summary Seasoned pharmaceutical and biotechnology executive successful in creating a culture-of-innovation to optimize value-based decision making. Adept at building sustainable product pipelines founded upon high performing teams that excel operationally and align decisions with organizational vision and asset strategies. Doubled portfolio productivity at a Fortune 50 company. Managed global resources of $1 billion/year within 1% of budget. Proven global leadership abilities with deep cultural awareness, including expatriation to France. Noted by peers as an honest leader with integrity who succeeds via collaborative leadership. Legacy of leading global program teams through development: EXUBERA, MACUGEN, AFREZZA, IMOVAX, MENACTRA, etc. Legacy of optimizing project and portfolio management tools, processes, and staff behaviors. Built a biotechnology development organization and subsequently managed technical, scientific, and medical personnel while creating an innovative and safe environment where staff could take personal ownership of the organizations success.

Organization and Position Summary

MannKind Corp. MannKind Corp. Pfizer Inc. Pfizer Inc. Sanofi-Pasteur Sanofi-Pasteur Boehringer-Ingelheim Boehringer-Ingelheim

Senior Vice President, Development


Vice President, Development/Project Management 2006-2010 Worldwide Portfolio Director, Senior Director Global Project Leader, Director Chef de Projet (Project Leader), Director Global Project Manager R&D Project Manager R&D Scientist 2004-2006 2001-2004 2000-2001 1998-2000 1994-1998 1991-1994

David F. Townson Ph.D, PMP

Experience MannKind Corporation, Danbury, CT Sr. Vice President, Development (2010 2011) 2006 - 2011

Responsible for leading the development organization of this biotechnology company, including Medical Development, Clinical and Scientific Operations, Scientific and Academic Relations, Project Management, and the Chief Medical Officer. Established organizational vision and subsequent implementation: Built a development organization and directed its senior executive staff. Led a total staff of 60 employees charged with all aspects of design, execution, and information reporting. Managed direct budget of $75MM/year. Chaired operations governance responsible for delivering portfolio assets supporting the corporate strategy. Developed product strategies to maximize program and portfolio value and well as value-based risk options. Authored public press releases, investor Q&A, Board Books, SEC filings (10-Ks, etc). Created key presentations for Board of Directors and interfaced with investment analysts.

Vice President, Development and Project Management (2006 - 2010)

Responsible for leading the creation and valuation of strategic investment opportunities as well as leading the organizations primary late stage product technology platform AFREZZA, a novel ultra-rapid acting inhaled insulin drug-device combination through development and NDA submission. Program Leader for AFREZZA Responsible for ensuring delivery of all product milestones and maintaining alignment across R&D, Production, and Commercial organizations. Managed project budget of $50MM/year. Primary point of communication for internal and investor messaging. Built PMO (Project Management Office): Created methodologies and processes for formally identifying, and consistently valuing life-cycle development investment opportunities to maximize portfolio value. Developed risk management valuation practice to drive risk buy-down options. Led R&D due diligence teams for partnership discussions and evaluations.

Pfizer, Inc., New London, CT Worldwide Portfolio Director, Senior Director (2004 2006)

2001 - 2006

Responsible for maximizing the value and output of the cardiovascular, metabolic, and endocrine disease (CVMED) product portfolio while operating within +/-2% of budget. Also accountable for partnering across the global organization to create and implement therapeutic area strategies to align the Research, Development, and Commercial organizations portfolio vision and long-term direction. Strategically and operationally led the organizations largest portfolio and delivered four NDAs in 2004 versus the corporate goal of two NDAs. Managed over $1BB in resources per year for this global asset category. Created and implemented concepts and methodology for therapeutic area portfolio value creation and served as Pfizers Subject-Matter Expert (SME) for portfolio management organizationally and externally. Led the introduction of the portfolio management practice to the Pfizer Japan organization. Team Leader for technical due diligence and negotiation deal team member for the purchase of EXUBERA rights from Sanofi-Aventis in 2006 for $1.3BB.

David F. Townson Ph.D, PMP

Global Project Leader, Director (2001 - 2004)
Accountable for leading Pfizer global drug development project teams in multiple therapeutic areas, such as diabetes, cardiovascular, and ophthalmology. Single point of accountability to executive management and governance. Led Pfizer teams for multiple alliance and co-development partnerships, R&D due diligence, etc. EXUBERA: Type 1 and type 2 diabetes, inhaled insulin - Approved in US and Europe. MACUGEN: Age-related macular degeneration. Approved in US and Europe. Alliance teams: Pfizer-Aventis, Pfizer-Nektar Therapeutics, Pfizer-Eyetech Pharmaceuticals. Managed project budgets up $60MM/year.

Sanofi-Pasteur, Lyon, France and Swiftwater, PA Chef de Projet (Project Leader), Director (2000 2001)

1998 2001

Accountable for leading global vaccine development project teams. Single point of accountability to executive management and governance. IMOVAX (second generation): Human rabies vaccine, chromatically purified. Managed R&D project budgets (up to $25MM) and delivered key corporate project goals.

Global Project Manager (1998-2000)

Responsible for all aspects of global operational execution of the late stage development and regulatory submissions (USA and Europe). MENACTRA: Tetravalent Meningitis vaccine (A, C, Y, W-135). Approved in USA and Europe. Liaison for alliance relationship with Merck team, based in Lyon France. Developed project prioritization methodology to improve portfolio execution globally.

Boehringer-Ingelheim, Ridgefield, CT Project Manager, R&D Project Management (1994 1998)

1991 1998

Responsible for providing project management support for numerous early development project teams from lab through IND submission. Assisted in transfer of responsibility of early development candidates to full development teams at the phase 2 stage gate. Project management liaison between R&D and late stage group. COMBIVENT UDV: For the treatment of Asthma/COPD - Unit dose vials. ATROVENT HFA: For the treatment of Asthma/COPD alternate propellant. Developed R&D resource management methodology to drive effective capacity planning and support annual budgetary requests.

David F. Townson Ph.D, PMP

R&D Scientist, Pharmaceutical Development (1991 1994)
Responsible for assisting in the effective development of technology transfer processes from clinical to commercial scale in Boehringer-Ingelheim R&D division. VIRAMUNE: For the treatment of HIV. Approved in USA and Europe. Created cleaning validation program for R&D clinical manufacturing projects.

Ph.D. M.A. Applied Management. Walden University School of Management. Minneapolis, MN. Business and Policy Studies. State University of New York, Empire State College. Albany, NY.

Graduate Certificate Program. Computer Applications. Long Island University, Dobbs Ferry, NY. B.S. Environmental Science. State University of New York, Fredonia, N.Y.

Project Management Professional (PMP), Project Management Institute (PMI), 1996-Present. Board Member, Green-Hill Martial Arts a Non-Profit organization. 2011 2012 Term. Board Member, Concepts Worldwide Advisory Board. 2008-2010. Board Member, PMI Southern New England Chapter, Board of Directors, 1995-1998. Boy Scouts of America - Troop 163, Monroe CT. Certified Parental Volunteer and Chaperone. 2010 - Present.

Industry Leadership/Recognition
Extensive list of pharmaceutical industry conference speaking engagements available upon request: Subjects include Value Management, Project and Portfolio Management, Risk Management, Strategic Decision-Making. Featured in recent cover article for Medical Meetings Magazine, June 2011, e-copy available at